Literature DB >> 25266027

Adenocarcinoma at the gastroesophageal junction.

Sahar Al-Haddad1, Andrew C Chang, Gert De Hertogh, Andrea Grin, Rupert Langer, Xavier Sagaert, Marianna Salemme, Catherine J Streutker, Geneviève Soucy, Monika Tripathi, Melissa P Upton, Michael Vieth, Vincenzo Villanacci.   

Abstract

The following, from the 12th OESO World Conference: Cancers of the Esophagus, includes commentaries on the clinical differences between carcinomas arising slightly above, slightly below, and within the gastroesophageal junction (GEJ); information provided by biopsies; information provided by resection specimens following neoadjuvant therapy; histologic differences existing between carcinomas arising slightly above, slightly below, and within the GEJ; differences provided by immunohistochemistry in these tumors; information given by endoscopic mucosal resection specimens; the role of esophageal pyloric gland adenomas as precursors of adenocarcinomas in the region of the cardia; the role of pancreatic metaplasia; Her2 immunoreactivity to make distinctions in the site of origin; and intestinal metaplasia limited to the cardia as a precursor of adenocarcinoma.
© 2014 New York Academy of Sciences.

Entities:  

Keywords:  Her2; OESO; gastroesophageal junction; immunohistochemistry; intestinal metaplasia; neoadjuvant; pyloric gland adenoma

Mesh:

Year:  2014        PMID: 25266027     DOI: 10.1111/nyas.12535

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  2 in total

1.  Gastrectomy compared to oesophagectomy for Siewert II and III gastro-oesophageal junctional cancer in relation to resection margins, lymphadenectomy and survival.

Authors:  Joonas H Kauppila; Karl Wahlin; Jesper Lagergren
Journal:  Sci Rep       Date:  2017-12-19       Impact factor: 4.379

2.  Outcomes of the Surgical Treatment for Adenocarcinoma of the Cardia - Single Institution Experience.

Authors:  Stojan Potrc; Arpad Ivanecz; Bojan Krebs; Urska Marolt; Bojan Iljevec; Tomaz Jagric
Journal:  Radiol Oncol       Date:  2017-09-14       Impact factor: 2.991

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.